Search
KB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Synonyms: (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINOOMS906
go.drugbank.com/drugs/DB17722InvestigationalOMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
Seliforant
go.drugbank.com/drugs/DB15220InvestigationalSeliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).
Nigericin
go.drugbank.com/drugs/DB14056ExperimentalIt is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)
Autologous Hematopoietic Peripheral Blood Stem Cells
go.drugbank.com/drugs/DB17067InvestigationalAutologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.
REC-994
go.drugbank.com/drugs/DB15616InvestigationalREC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Synonyms: N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamideAG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
VAD-044
go.drugbank.com/drugs/DB17697InvestigationalVAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]
Paramethadione
go.drugbank.com/drugs/DB00617ApprovedParamethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.